TG Therapeutics, Inc. or Bausch Health Companies Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: Bausch vs. TG Therapeutics

__timestampBausch Health Companies Inc.TG Therapeutics, Inc.
Wednesday, January 1, 2014202630000024518692
Thursday, January 1, 2015268270000019886580
Friday, January 1, 2016281000000012631689
Sunday, January 1, 2017258200000021977998
Monday, January 1, 2018247300000020759000
Tuesday, January 1, 2019255400000020838000
Wednesday, January 1, 20202367000000121812000
Friday, January 1, 20212624000000152137000
Saturday, January 1, 2022262500000083231000
Sunday, January 1, 20232917000000122706000
Loading chart...

Infusing magic into the data realm

SG&A Cost Management: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Bausch Health Companies Inc. and TG Therapeutics, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Bausch Health consistently reported SG&A expenses averaging around $2.57 billion annually, with a peak of $2.92 billion in 2023. In contrast, TG Therapeutics maintained a much leaner operation, with expenses averaging $60 million, peaking at $152 million in 2021.

Bausch Health's expenses are approximately 43 times higher than TG Therapeutics, reflecting its larger scale and market presence. However, TG Therapeutics' ability to keep costs low while navigating the competitive biotech sector is noteworthy. This comparison highlights the diverse strategies companies employ to manage operational costs, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025